Products
Burfiralimab Biosimilar Monoclonal Antibody (Vimentin) for Research
Cat No.: GMP-Bios-INN-1117
Anti-VIM therapeutic antibody (Pre-made Burfiralimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Burfiralimab (development code hzVSF) is a monoclonal antibody targeting vimentin (VIM). It is developed by ImmuneMed for COVID-19 pneumonia, pneumonia, hepatitis B among others. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1117-1mg | 1mg | 3090 |
| GMP-Bios-INN-1117-10mg | 10mg | |
| GMP-Bios-INN-1117-100mg | 100mg | |
| GMP-Bios-INN-1117-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Burfiralimab biosimilar, Whole mAb, Anti-VIM Antibody: Anti-VIM/Vimentin therapeutic antibody |
| INN Name | Burfiralimab |
| Target | VIM |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | ImmuneMed |
| Conditions Approved | na |
| Conditions Active | COVID-19 Pneumonia;Pneumonia;Hepatitis B;Alcholic hepatitis;Non-alcoholic steatohepatitis;Psoriasis;Scleroderma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
